Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors
Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype, with a poor survival rate compared to others subtypes. For a long time, chemotherapy was the only systemic treatment for TNBC, and the identification of actionable molecular targets might ultimately improve the prognosis...
Main Authors: | Alexey I. Kalinkin, Vladimir O. Sigin, Ekaterina B. Kuznetsova, Ekaterina O. Ignatova, Ilya I. Vinogradov, Maxim I. Vinogradov, Igor Y. Vinogradov, Dmitry V. Zaletaev, Marina V. Nemtsova, Sergey I. Kutsev, Alexander S. Tanas, Vladimir V. Strelnikov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/24/17343 |
Similar Items
-
DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer
by: Vladimir O. Sigin, et al.
Published: (2023-03-01) -
Upregulation of Leukotriene Receptors in Gastric Cancer
by: Daniel Schubert, et al.
Published: (2011-08-01) -
The Role of Leukotrienes in the Development of Broncho-Obstructive Syndrome
by: Ye.I. Yulish, et al.
Published: (2013-08-01) -
Non-obvious effects of montelukast – leukotriene receptor blocker: frigoprotective and anticonvulsant properties
by: S.Yu. Shtrygol, et al.
Published: (2021-06-01) -
Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer’s Disease mice
by: J. Michael, et al.
Published: (2020-08-01)